{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:08:39Z","timestamp":1792202919925,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.burns.2018.12.018","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:36:45Z","timestamp":1566837405000},"page":"1634-1638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.1016","volume":"45","author":[{"given":"Christopher H.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3035-6476","authenticated-orcid":false,"given":"T. Justin","family":"Gillenwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nagengast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan C.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren L.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.burns.2018.12.018_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.burns.2018.12.018_bib0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.burns.2018.12.018_bib0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"issue":"6","key":"10.1016\/j.burns.2018.12.018_bib0020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.burns.2018.12.018_bib0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.burns.2018.12.018_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int Ophthalmol Clin"},{"issue":"6","key":"10.1016\/j.burns.2018.12.018_bib0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.burns.2018.12.018_bib0040","first-page":"61","article-title":"Toxic epidermal necrolysis successfully treated with infliximab","volume":"23","author":"Zarate-Correa","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"10.1016\/j.burns.2018.12.018_bib0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.burns.2018.12.018_bib0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2018.12.018_bib0055","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2018.12.018_bib0060","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/00015550510037062","article-title":"Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab","volume":"85","author":"Al-Shouli","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2018.12.018_bib0065","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2018.12.018_bib0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.burns.2018.12.018_bib0075","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/pde.12029","article-title":"Toxic epidermal necrolysis in a child successfully treated with infliximab","volume":"31","author":"Scott-Lang","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.burns.2018.12.018_bib0080","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.burns.2018.12.018_bib0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"10.1016\/j.burns.2018.12.018_bib0090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1365-4632.2008.04020.x","article-title":"Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis\/toxic epidermal necrolysis: definition of a new model based on translational research","volume":"48","author":"Sadighha","year":"2009","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.burns.2018.12.018_bib0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.burns.2018.12.018_bib0100","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2018.12.018_bib0105","first-page":"21","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis and treatment with a biologic: a case report","author":"Chong","year":"2017","journal-title":"Perm J"},{"issue":"1","key":"10.1016\/j.burns.2018.12.018_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.burns.2018.12.018_bib0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"issue":"1","key":"10.1016\/j.burns.2018.12.018_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.burns.2018.12.018_bib0125","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute stevens-johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.burns.2018.12.018_bib0130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.burns.2018.12.018_bib0135","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.burns.2018.12.018_bib0140","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.burns.2018.12.018_bib0145","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2567.2001.01310.x","article-title":"Acholeplasma laidlawii up-regulates granulysin gene expression via transcription factor activator protein-1 in a human monocytic cell line, THP-1","volume":"104","author":"Kida","year":"2001","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.burns.2018.12.018_bib0150","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.burns.2018.12.018_bib0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"issue":"9140","key":"10.1016\/j.burns.2018.12.018_bib0160","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.burns.2018.12.018_bib0165","first-page":"33","article-title":"What are the risks of biologic therapy in rheumatoid arthritis? An update on safety","volume":"65","author":"Weisman","year":"2002","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.burns.2018.12.018_bib0170","unstructured":"Amgen. Etanercept (Enbrel) Product Information. http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/enbrel\/enbrel_pi.pdf. Published 2017. [Accessed 12\/25, 2017]."}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417918308131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417918308131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:52:01Z","timestamp":1721649121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417918308131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0305417918308131"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2018.12.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736554834.793575143","asserted-by":"object"}]},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2018.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}